Covered recipient · General Payments record
OLUSOLA JOSEPH
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$1,313.63
- Reported across 81 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $325.25 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $90.35 | 4 |
| PFIZER INC. | $58.06 | 4 |
| SHIELD THERAPEUTICS INC | $37.11 | 2 |
| Exact Sciences Corporation | $32.70 | 1 |
| Acerta Pharma LLC | $30.97 | 2 |
| DEXCOM, INC. | $22.93 | 1 |
| Novo Nordisk AS | $18.72 | 1 |
| Gilead Sciences, Inc. | $18.39 | 1 |
| Organon LLC | $16.02 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $15.84 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105531236 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.13 | 07/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105871521 | CMS |
| Dexcom, Inc. | $22.93 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153381760 | CMS |
| Exact Sciences Corporation | $32.70 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114723684 | CMS |
| Gilead Sciences, Inc. | $18.39 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133709157 | CMS |
| Lilly USA, LLC | $23.77 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135852751 | CMS |
| Lilly USA, LLC | $21.57 | 03/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135916473 | CMS |
| Lilly USA, LLC | $26.08 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135916475 | CMS |
| Lilly USA, LLC | $18.93 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135916095 | CMS |
| Novo Nordisk Inc | $18.72 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100445611 | CMS |
| Organon Llc | $16.02 | 06/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136262822 | CMS |
| PFIZER INC. | $13.72 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130931539 | CMS |
| PFIZER INC. | $17.39 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130932039 | CMS |
| PFIZER INC. | $13.23 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130934840 | CMS |
| PFIZER INC. | $13.72 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130940916 | CMS |
| SHIELD THERAPEUTICS INC | $18.05 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150126131 | CMS |
| SHIELD THERAPEUTICS INC | $19.06 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150142102 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.